image dons

I make a donation

ADMIRAL

National multicentric trial aiming to evaluate the impact of Abciximab versus placebo in patients with an acute coronary syndrome with ST segment elevation and treated with angioplasty

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

logo étude

objectif

Impact of Abciximab versus placebo in patients with an acute coronary syndrome with ST segment elevation and treated with angioplasty

date de réalisation

1999

nombre de patients

300

nombre de centres participants

26 French centers

type de financement

Private (Lilly)

Publications

  • Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
    G Montalescot, P Barragan, O Wittenberg, P Ecollan, S Elhadad, P Villain, J M Boulenc, M C Morice, L Maillard, M Pansiéri, R Choussat, P Pinton, ADMIRAL Investigators
    Publicated in The New England Journal of Medecine
  • Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention
    J P Collet, G Montalescot, C Lesty, Z Mishal, J Soria, R Choussat, G Drobinski, C Soria, P Pinton, P Barragan, D Thomas
    Publicated in Circulation

Autres études

+

ABYSS

En cours


Phase 4 trial, evaluating the interest of betablocking treatment in the long term treatment of non-complicated myocardial infarct.
+

AMUNDSEN

En cours


A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....
+

ARCACHON

En cours


To demonstrate the non-inferiority of a strategy of simple clinical follow-up (without non-invasive stress testing) in asymptomatic CAD patients with a prior history of coronary revascularization comp...